Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CDK5RAP3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CDK5RAP3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CDK5RAP3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CDK5RAP3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CDK5RAP3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CDK5RAP3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CDK5RAP3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CDK5RAP3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000007512 | Skin | cSCC | cell cycle checkpoint | 68/4864 | 169/18723 | 3.37e-05 | 3.67e-04 | 68 |
GO:004483911 | Skin | cSCC | cell cycle G2/M phase transition | 61/4864 | 148/18723 | 3.61e-05 | 3.90e-04 | 61 |
GO:00070935 | Skin | cSCC | mitotic cell cycle checkpoint | 54/4864 | 129/18723 | 5.99e-05 | 5.87e-04 | 54 |
GO:004277015 | Skin | cSCC | signal transduction in response to DNA damage | 68/4864 | 172/18723 | 6.48e-05 | 6.31e-04 | 68 |
GO:00000795 | Skin | cSCC | regulation of cyclin-dependent protein serine/threonine kinase activity | 41/4864 | 94/18723 | 1.53e-04 | 1.35e-03 | 41 |
GO:190402911 | Skin | cSCC | regulation of cyclin-dependent protein kinase activity | 42/4864 | 98/18723 | 2.05e-04 | 1.70e-03 | 42 |
GO:007190024 | Skin | cSCC | regulation of protein serine/threonine kinase activity | 123/4864 | 359/18723 | 2.70e-04 | 2.17e-03 | 123 |
GO:190179829 | Skin | cSCC | positive regulation of signal transduction by p53 class mediator | 14/4864 | 25/18723 | 1.37e-03 | 8.68e-03 | 14 |
GO:0035303112 | Skin | cSCC | regulation of dephosphorylation | 49/4864 | 128/18723 | 1.46e-03 | 9.17e-03 | 49 |
GO:0006469110 | Skin | cSCC | negative regulation of protein kinase activity | 74/4864 | 212/18723 | 2.36e-03 | 1.37e-02 | 74 |
GO:001631115 | Skin | cSCC | dephosphorylation | 134/4864 | 417/18723 | 2.65e-03 | 1.50e-02 | 134 |
GO:0033673110 | Skin | cSCC | negative regulation of kinase activity | 81/4864 | 237/18723 | 2.95e-03 | 1.64e-02 | 81 |
GO:00103892 | Skin | cSCC | regulation of G2/M transition of mitotic cell cycle | 37/4864 | 94/18723 | 3.02e-03 | 1.67e-02 | 37 |
GO:19027492 | Skin | cSCC | regulation of cell cycle G2/M phase transition | 38/4864 | 102/18723 | 7.85e-03 | 3.65e-02 | 38 |
GO:0042176113 | Thyroid | PTC | regulation of protein catabolic process | 231/5968 | 391/18723 | 4.76e-29 | 2.14e-26 | 231 |
GO:1903362113 | Thyroid | PTC | regulation of cellular protein catabolic process | 162/5968 | 255/18723 | 1.62e-25 | 5.12e-23 | 162 |
GO:0034976113 | Thyroid | PTC | response to endoplasmic reticulum stress | 161/5968 | 256/18723 | 1.14e-24 | 3.27e-22 | 161 |
GO:0034504111 | Thyroid | PTC | protein localization to nucleus | 170/5968 | 290/18723 | 3.34e-21 | 6.38e-19 | 170 |
GO:1903320113 | Thyroid | PTC | regulation of protein modification by small protein conjugation or removal | 148/5968 | 242/18723 | 4.49e-21 | 8.10e-19 | 148 |
GO:1903829113 | Thyroid | PTC | positive regulation of cellular protein localization | 162/5968 | 276/18723 | 2.40e-20 | 3.52e-18 | 162 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDK5RAP3 | SNV | Missense_Mutation | novel | c.814N>T | p.Pro272Ser | p.P272S | Q96JB5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
CDK5RAP3 | SNV | Missense_Mutation | novel | c.1164C>A | p.Phe388Leu | p.F388L | Q96JB5 | protein_coding | deleterious(0.03) | probably_damaging(0.997) | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR |
CDK5RAP3 | SNV | Missense_Mutation | novel | c.371N>G | p.Glu124Gly | p.E124G | Q96JB5 | protein_coding | deleterious(0) | possibly_damaging(0.894) | TCGA-C8-A273-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CDK5RAP3 | SNV | Missense_Mutation | novel | c.371N>G | p.Glu124Gly | p.E124G | Q96JB5 | protein_coding | deleterious(0) | possibly_damaging(0.894) | TCGA-E9-A1NF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
CDK5RAP3 | insertion | Frame_Shift_Ins | novel | c.354_355insGGCCC | p.Met119GlyfsTer3 | p.M119Gfs*3 | Q96JB5 | protein_coding | | | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD |
CDK5RAP3 | insertion | Nonsense_Mutation | novel | c.355_356insGACTTTGAGAGGTCAGTCCCAT | p.Met119ArgfsTer3 | p.M119Rfs*3 | Q96JB5 | protein_coding | | | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD |
CDK5RAP3 | deletion | Frame_Shift_Del | novel | c.528delN | p.Ala177GlnfsTer32 | p.A177Qfs*32 | Q96JB5 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CDK5RAP3 | SNV | Missense_Mutation | | c.832C>T | p.Pro278Ser | p.P278S | Q96JB5 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-C5-A7CO-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
CDK5RAP3 | SNV | Missense_Mutation | | c.530N>A | p.Ala177Glu | p.A177E | Q96JB5 | protein_coding | tolerated(0.94) | benign(0.148) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
CDK5RAP3 | SNV | Missense_Mutation | | c.450G>T | p.Glu150Asp | p.E150D | Q96JB5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |